Unum Therapeutics Inc. announced that on May 14, 2020, Unum Therapeutics Inc. terminated the employment of Matthew Osborne, the company's Chief Financial Officer, effective as of May 29, 2020. Mr. Osborne's separation from the company constitutes a termination without cause as defined in that certain Employment Agreement, dated as of June 17, 2019, between the company and Mr. Osborne filed as Exhibit 10.2 to the company's Quarterly Report on Form 10-Q filed August 12, 2019. Mr. Osborne's termination did not result from a disagreement with the company on any matter relating to the Company's operations, policies or practices, including its controls or financial related matters.

Mr. Osborne's termination is in connection with the company's decision to enter into a strategic process with Ladenburg Thalmann & Co. and the company's continuing efforts to conserve resources. On May 14, 2020, the Board of Directors of the company appointed John Green as the principal financial officer of the company, effective as of the date of Mr. Osborne's termination of employment.

Mr. Green currently serves as the principal accounting officer and Vice President of Finance and Controller of the company and will continue in those roles while serving as the principal financial officer of the company.